Odonate, Inc.

ODT

US6760793041

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 02:00:48 10/05/2024 am IST			5-day change	1st Jan Change
2,850 ^USD	-83.34%		0.00%	-81.00%

2023	North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	DJ
2023	North American Morning Briefing : Stock Futures -2-	DJ

Odonate Therapeutics, Inc. Announces Resignation of Jeff Vacirca as Director

September 28, 2019 at 01:35 am IST

On September 23, 2019, Jeff Vacirca, M.D. resigned as a director of Odonate Therapeutics, Inc. Dr. Vacirca's resignation was not the result of any disagreement with the Company.

Latest news about Odonate, Inc.

North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	23/23/23	DJ
North American Morning Briefing : Stock Futures -2-	16/23/16	DJ
North American Morning Briefing : Caution Ahead of Fed, Inflation Data to Hold Back Stocks	09/23/09	DJ
North American Morning Briefing : Stock Futures -2-	02/23/02	DJ
North American Morning Briefing : Investors Await -2-	26/23/26	DJ
North American Morning Briefing : Powell on Tap -2-	19/23/19	DJ
North American Morning Briefing : Hopes of Easing -2-	12/23/12	DJ
North American Morning Briefing : Caution -2-	14/23/14	DJ
North American Morning Briefing : Stock Futures -2-	20/22/20	DJ
North American Morning Briefing : Tech Futures -2-	13/22/13	DJ
North American Morning Briefing : Stocks Waver, -3-	12/22/12	DJ
North American Morning Briefing : Stocks to Open -3-	22/22/22	DJ
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P Global BMI Index	20/22/20	CI
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P TMI Index	20/22/20	CI
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Composite Index	17/22/17	CI
Top Midday Decliners	08/22/08	MT
Odonate Therapeutics Gets Nasdaq Notice to Delist Shares	07/22/07	MT
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Biotechnology Index	17/21/17	CI
Insider Sell: Odonate Therapeutics	22/21/22	MT
Odonate Therapeutics Plans Share Buybacks After Halting Development of Breast Cancer Drug	17/21/17	MT
Odonate Therapeutics, Inc. announces an Equity Buyback for 20,000,000 shares, representing 51.95% of its issued share capital.	17/21/17	CI
Odonate Therapeutics, Inc. authorizes a Buyback Plan.	17/21/17	CI
Odonate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	11/21/11	CI
North American Morning Briefing : Stock Futures -3-	10/21/10	DJ
Odonate Therapeutics, Inc. Announces Termination of Joseph O’Connell as Chief Medical Officer	06/21/06	CI

Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ODONATE, INC.	-81.00%	8.09M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals

Odonate, Inc.

Equities

ODT

US6760793041

Pharmaceuticals

Odonate Therapeutics, Inc. Announces Resignation of Jeff Vacirca as Director

Latest news about Odonate, Inc.

Chart Odonate, Inc.

Company Profile

Sector Other Pharmaceuticals